Development of Parkinson's disease in patients with Narcolepsy

Journal of Neural Transmission

Volumn 119, Issue 6, 2012, Pages 697-699

  Christine, Chadwick W ^a   Marks Jr , William J ^a   Ostrem, Jill L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dextroamphetamine; Risk factor; Somnolence; Treatment

Indexed keywords

DEXAMPHETAMINE; LEVODOPA; RASAGILINE;

ADULT; ARTICLE; BRADYKINESIA; BRAIN DEPTH STIMULATION; CASE REPORT; CATAPLEXY; DAYTIME SOMNOLENCE; DISEASE ASSOCIATION; FEMALE; HANDWRITING; HUMAN; HYPOMIMIA; LIMB TREMOR; MALE; NARCOLEPSY; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGE OF ONSET; ANTIPARKINSON AGENTS; CATAPLEXY; CENTRAL NERVOUS SYSTEM STIMULANTS; DEEP BRAIN STIMULATION; DEXTROAMPHETAMINE; FEMALE; HUMANS; HYPOKINESIA; INDANS; INTERNATIONAL CLASSIFICATION OF DISEASES; LEVODOPA; MALE; MIDDLE AGED; NARCOLEPSY; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SLEEP; YOUNG ADULT;

EID: 84863448403     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-011-0761-z     Document Type: Article

References (12)

1. Abbott RD, Ross GW, White LR, Tanner CM, Masaki KH, Nelson JS, Curb JD, Petrovitch H (2005) Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 65:1442-1446
2. American Academy of Sleep Medicine (2005). The International classification of sleep disorders: diagnostic and coding manual, 2nd edn. American Academy of Sleep Medicine, Westchester
3. Callaghan RC, Cunningham JK, Sajeev G, Kish SJ (2010) Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders. Mov Disord 25:2333-2339
4. Davidson C, Gow AJ, Lee TH, Ellinwood EH (2001) Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 36:1-22
5. Garwood ER, Bekele W, McCulloch CE, Christine CW (2006) Amphetamine exposure is elevated in Parkinson's disease. Neurotoxicology 27:1003-1006
6. Guilarte TR (2001) Is methamphetamine abuse a risk factor in Parkinsonism? Neurotoxicology 22:725-731
7. Maeda T, Nagata K, Kondo H, Kanbayashi T (2006) Parkinson's disease comorbid with narcolepsy presenting low CSF hypocretin/ orexin level. Sleep Med 7:662
8. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA (1998) Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35, 428. J Neurosci 18:8417-8422
9. Ohayon MM, Priest RG, Zulley J, Smirne S, Paiva T (2002) Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology 58:1826-1833
10. Ricaurte GA, Mechan AO, Yuan J, Hatzidimitriou G, Xie T, Mayne AH, McCann UD (2005) Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates. J Pharmacol Exp Ther 315:91-98
11. Silber MH, Krahn LE, Olson EJ, Pankratz VS (2002) The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep 25:197-202
12. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699-703